Regulation of β2-adrenergic receptor function by conformationally selective single-domain intrabodies
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Regulation of β2-adrenergic receptor function by conformationally selective single-domain intrabodies. / Staus, Dean P; Wingler, Laura M; Strachan, Ryan T; Rasmussen, Søren Gøgsig Faarup; Pardon, Els; Ahn, Seungkirl; Steyaert, Jan; Kobilka, Brian K; Lefkowitz, Robert J.
In: Molecular Pharmacology, Vol. 85, No. 3, 03.2014, p. 472-81.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Regulation of β2-adrenergic receptor function by conformationally selective single-domain intrabodies
AU - Staus, Dean P
AU - Wingler, Laura M
AU - Strachan, Ryan T
AU - Rasmussen, Søren Gøgsig Faarup
AU - Pardon, Els
AU - Ahn, Seungkirl
AU - Steyaert, Jan
AU - Kobilka, Brian K
AU - Lefkowitz, Robert J
PY - 2014/3
Y1 - 2014/3
N2 - The biologic activity induced by ligand binding to orthosteric or allosteric sites on a G protein-coupled receptor (GPCR) is mediated by stabilization of specific receptor conformations. In the case of the β2 adrenergic receptor, these ligands are generally small-molecule agonists or antagonists. However, a monomeric single-domain antibody (nanobody) from the Camelid family was recently found to allosterically bind and stabilize an active conformation of the β2-adrenergic receptor (β2AR). Here, we set out to study the functional interaction of 18 related nanobodies with the β2AR to investigate their roles as novel tools for studying GPCR biology. Our studies revealed several sequence-related nanobody families with preferences for active (agonist-occupied) or inactive (antagonist-occupied) receptors. Flow cytometry analysis indicates that all nanobodies bind to epitopes displayed on the intracellular receptor surface; therefore, we transiently expressed them intracellularly as "intrabodies" to test their effects on β2AR-dependent signaling. Conformational specificity was preserved after intrabody conversion as demonstrated by the ability for the intracellularly expressed nanobodies to selectively bind agonist- or antagonist-occupied receptors. When expressed as intrabodies, they inhibited G protein activation (cyclic AMP accumulation), G protein-coupled receptor kinase (GRK)-mediated receptor phosphorylation, β-arrestin recruitment, and receptor internalization to varying extents. These functional effects were likely due to either steric blockade of downstream effector (Gs, β-arrestin, GRK) interactions or stabilization of specific receptor conformations which do not support effector coupling. Together, these findings strongly implicate nanobody-derived intrabodies as novel tools to study GPCR biology.
AB - The biologic activity induced by ligand binding to orthosteric or allosteric sites on a G protein-coupled receptor (GPCR) is mediated by stabilization of specific receptor conformations. In the case of the β2 adrenergic receptor, these ligands are generally small-molecule agonists or antagonists. However, a monomeric single-domain antibody (nanobody) from the Camelid family was recently found to allosterically bind and stabilize an active conformation of the β2-adrenergic receptor (β2AR). Here, we set out to study the functional interaction of 18 related nanobodies with the β2AR to investigate their roles as novel tools for studying GPCR biology. Our studies revealed several sequence-related nanobody families with preferences for active (agonist-occupied) or inactive (antagonist-occupied) receptors. Flow cytometry analysis indicates that all nanobodies bind to epitopes displayed on the intracellular receptor surface; therefore, we transiently expressed them intracellularly as "intrabodies" to test their effects on β2AR-dependent signaling. Conformational specificity was preserved after intrabody conversion as demonstrated by the ability for the intracellularly expressed nanobodies to selectively bind agonist- or antagonist-occupied receptors. When expressed as intrabodies, they inhibited G protein activation (cyclic AMP accumulation), G protein-coupled receptor kinase (GRK)-mediated receptor phosphorylation, β-arrestin recruitment, and receptor internalization to varying extents. These functional effects were likely due to either steric blockade of downstream effector (Gs, β-arrestin, GRK) interactions or stabilization of specific receptor conformations which do not support effector coupling. Together, these findings strongly implicate nanobody-derived intrabodies as novel tools to study GPCR biology.
KW - Amino Acid Sequence
KW - Cell Line
KW - Cyclic AMP
KW - G-Protein-Coupled Receptor Kinases
KW - HEK293 Cells
KW - Humans
KW - Molecular Sequence Data
KW - Phosphorylation
KW - Protein Binding
KW - Receptors, Adrenergic, beta-2
KW - Receptors, G-Protein-Coupled
KW - Sequence Alignment
KW - Single-Domain Antibodies
U2 - 10.1124/mol.113.089516
DO - 10.1124/mol.113.089516
M3 - Journal article
C2 - 24319111
VL - 85
SP - 472
EP - 481
JO - Molecular Pharmacology
JF - Molecular Pharmacology
SN - 0026-895X
IS - 3
ER -
ID: 120587026